Liver International: 肝移植术后早期冠心病与心血管事件发生的关系

2019-07-26 不详 MedSci原创

心血管并发症是肝移植(LT)后死亡的主要原因。然而,冠状动脉疾病(CAD)对这些并发症的影响尚不清楚,本项研究根据冠状动脉血管造影定量CAD的严重程度对LT的心血管事件进行了危险分层评估。

背景与目的
血管并发症是肝移植(LT)后死亡的主要原因。然而,冠状动脉疾病(CAD)对这些并发症的影响尚不清楚,本项研究根据冠状动脉血管造影定量CAD的严重程度对LT的心血管事件进行了危险分层评估。

方法
研究人员对2010年1月至2017年1月期间所有患有LT的患者均进行了评估(N = 348),但分析仅限于在LT之前进行冠状动脉造影的患者(N = 283)。所有患者年龄> 50岁,均有CAD病史,心脏压力测试异常或CAD危险因素均进行冠状动脉造影。主要观察结果是心血管事件,包括心肌梗塞(MI),心脏骤停,中风,心脏死亡,心力衰竭或LT后4周内发生的心律失常。

结果
有92例(32.5%)患有CAD,32例(11.3%)有阻塞性CAD。在研究期间,72名(25.4%)患者符合原发性心血管病,最常见的是心律失常(N = 59,20.8%)。11例(3.9%)患者发生非ST段抬高心肌梗死。共发生10例死亡(3.5%),其中6例(2.1%)可归因于心源性死亡。没有证据表明CAD和心血管事件的存在和严重程度之间存在关联。在多元回归模型中,只有糖尿病[OR 2.62,95%CI(1.49,4.64),P  <0.001]与心血管事件发生的可能性相关。

结论
心血管疾病死亡率是LT后早期死亡率的最重要因素,但与CAD的严重程度无关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883791, encodeId=3d6f1883e914f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 22 05:32:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643627, encodeId=fdbe164362e76, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Apr 05 15:32:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998981, encodeId=99f81998981c6, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Dec 15 23:32:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008751, encodeId=de3e2008e5199, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Nov 10 06:32:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2020-02-22 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883791, encodeId=3d6f1883e914f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 22 05:32:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643627, encodeId=fdbe164362e76, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Apr 05 15:32:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998981, encodeId=99f81998981c6, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Dec 15 23:32:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008751, encodeId=de3e2008e5199, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Nov 10 06:32:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883791, encodeId=3d6f1883e914f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 22 05:32:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643627, encodeId=fdbe164362e76, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Apr 05 15:32:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998981, encodeId=99f81998981c6, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Dec 15 23:32:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008751, encodeId=de3e2008e5199, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Nov 10 06:32:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-12-15 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883791, encodeId=3d6f1883e914f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 22 05:32:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643627, encodeId=fdbe164362e76, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Apr 05 15:32:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998981, encodeId=99f81998981c6, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Dec 15 23:32:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008751, encodeId=de3e2008e5199, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Nov 10 06:32:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-10 般若傻瓜

相关资讯

AJCN:中心性肥胖测量与HIV患者心血管疾病风险的预测指标高度一致

研究人员发现接受高活性抗逆转录病毒疗法(HAART)的HIV患者体内体脂会重新分布,其代谢异常常会促成动脉粥样硬化,增加心血管疾病风险。本项研究旨在评估找出与HIV患者动脉粥样硬化相关的指标。

JAMA surg: 阿片类药物使用障碍患者行心血管手术的趋势和结果

持续使用阿片类药物是目前主要的医疗保健危机,而且目前对于阿片类药物使用障碍(OUD)患者接受心脏手术的效果缺乏一定程度的了解,因此,本项研究旨在探究存在OUD患者与非OUD患者行心脏手术后治疗效果是否存在差异。

AP&T:心血管风险评分以及血小板体积在预测非酒精性脂肪性肝病患者心血管事件发生率中的作用

动脉粥样硬化性心血管疾病是非酒精性脂肪性肝病(NAFLD)发病的关键原因,但目前尚缺乏预测主要急性心血管事件(MACE)的适当方法,因此,本项研究旨在在NAFLD患者中设计定制的心血管风险评分模型来预测此类事件发生的风险。

JAMA Cardiol:收缩压与心脏瓣膜病的关系

心脏瓣膜病是由哪些因素造成的目前还不清楚,本项研究旨在评估收缩压(BP)与心脏瓣膜病之间的关系。

Stroke: 地中海饮食可降低患有心血管疾病风险特征的人发生卒中的风险

有文献报道地中海饮食(MD)对卒中具有保护作用,但很少有研究调查这种关系是否因性别或心血管疾病风险而会有变化。

Hepatology:小密度低密度脂蛋白胆固醇可以预测肝移植受者的心血管事件发生情况

心血管疾病(CVD)是肝移植(LT)后发病率和死亡率的重要原因。尽管LT与血脂异常有关,特别是致动脉粥样硬化脂蛋白亚颗粒,但这些亚颗粒对CVD相关事件的影响尚不清楚。因此,本研究的目的是评估小密度(sdLDL-C)低密度脂蛋白(LDL)胆固醇(LDL-C)对CVD事件的影响。